Skip to main content
Top
Published in: BMC Urology 1/2019

Open Access 01-12-2019 | Prostate Cancer | Research article

Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden

Authors: Ulrika Rönningås, Per Fransson, Maja Holm, Agneta Wennman-Larsen

Published in: BMC Urology | Issue 1/2019

Login to get access

Abstract

Background

The prostate-specific antigen (PSA) -value is often used during the prostate cancer trajectory as a marker of progression or response to treatment. Concerns about PSA-values are often expressed by patients in clinical situations. Today there is a lack of larger studies that have investigated the association between PSA-value and distress. The aim was to investigate the association between PSA-values and distress adjusted for sociodemographic factors, hormonal therapy and quality of life (QoL), among men with prostate cancer.

Methods

In this cross-sectional survey of 3165 men with prostate cancer, members of the Swedish Prostate Cancer Federation, answered questions about sociodemographic factors, PSA, distress, QoL and treatments. Descriptive statistics, and bivariate and multivariable analyses were performed. The result was presented based on four PSA-value groups: 0–19, 20–99, 100–999, and ≥ 1000 ng/ml.

Results

Of the men, 53% experienced distress. An association between distress and PSA-values was found where higher PSA-values were associated with higher OR:s for experiencing distress in the different PSA-groups: 0–19 ng/ml (ref 1), 20–99 ng/ml (OR 1.25, 95% CI 1.01–1.55), 100–999 ng/ml (OR 1.47, 95% CI 1.12–1.94), ≥1000 ng/ml (OR 1.77, 95% CI 1.11–2.85). These associations were adjusted for sociodemographic factors and hormonal therapy. In the multivariable analyses, beside PSA-values, higher levels of distress were associated with being without partner or hormonal therapy. When adding QoL in the multivariable analysis, the association between PSA and distress did not remain significant.

Conclusion

These results indicate that the PSA-values are associated with distress, especially for those with higher values. However, to be able to support these men, continued research is needed to gain more knowledge about the mechanisms behind the association between emotional distress and PSA-values.
Literature
2.
go back to reference Lynch T, Burgess M. Prostate-specific antigen test: an informed choice. Prim Health Care. 2011;21(3):16–21.CrossRef Lynch T, Burgess M. Prostate-specific antigen test: an informed choice. Prim Health Care. 2011;21(3):16–21.CrossRef
3.
go back to reference Appleton L, Wyatt D, Perkins E, Parker C, Crane J, Jones A, Moorhead L, Brown V, Wall C, Pagett M. The impact of prostate cancer on men's everyday life. Eur J Cancer Care. 2015;24(1):71–84.CrossRef Appleton L, Wyatt D, Perkins E, Parker C, Crane J, Jones A, Moorhead L, Brown V, Wall C, Pagett M. The impact of prostate cancer on men's everyday life. Eur J Cancer Care. 2015;24(1):71–84.CrossRef
4.
go back to reference Roth A, Passik S. Anxiety in men with prostate cancer may interfere with effective managment of the disease. Prim Care Cancer. 1996;16:30. Roth A, Passik S. Anxiety in men with prostate cancer may interfere with effective managment of the disease. Prim Care Cancer. 1996;16:30.
5.
go back to reference van de Wal M, van Oort I, Schouten J, Thewes B, Gielissen M, Prins J. Fear of cancer recurrence in prostate cancer survivors. Acta Oncol. 2016;55(7):821–7.CrossRef van de Wal M, van Oort I, Schouten J, Thewes B, Gielissen M, Prins J. Fear of cancer recurrence in prostate cancer survivors. Acta Oncol. 2016;55(7):821–7.CrossRef
6.
go back to reference Hedestig O, Sandman P-O, Widmark A, Rasmussen BH. Meanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment. Scand J Urol Nephrol. 2008;42(2):101–9.CrossRef Hedestig O, Sandman P-O, Widmark A, Rasmussen BH. Meanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment. Scand J Urol Nephrol. 2008;42(2):101–9.CrossRef
7.
go back to reference Shen MJ, Nelson CJ, Peters E, Slovin SF, Hall SJ, Hall M, Herrera PC, Leventhal EA, Leventhal H, Diefenbach MA. Decision-making processes among prostate Cancer survivors with rising PSA levels: results from a qualitative analysis. Med Decis Making. 2015;35(4):477–86.CrossRef Shen MJ, Nelson CJ, Peters E, Slovin SF, Hall SJ, Hall M, Herrera PC, Leventhal EA, Leventhal H, Diefenbach MA. Decision-making processes among prostate Cancer survivors with rising PSA levels: results from a qualitative analysis. Med Decis Making. 2015;35(4):477–86.CrossRef
8.
go back to reference Lofters A, Juffs HG, Pond GR, Tannock IF. “PSA-itis”: knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate Cancer. J Urol. 2002;168(6):2516–20.CrossRef Lofters A, Juffs HG, Pond GR, Tannock IF. “PSA-itis”: knowledge of serum prostate specific antigen and other causes of anxiety in men with metastatic prostate Cancer. J Urol. 2002;168(6):2516–20.CrossRef
9.
go back to reference Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010;13(5):613–23.CrossRef Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010;13(5):613–23.CrossRef
10.
go back to reference Nanton V, Docherty A, Meystre C, Dale J. Finding a pathway: information and uncertainty along the prostate cancer patient journey. Br J Health Psychol. 2009;14(3):437–58.CrossRef Nanton V, Docherty A, Meystre C, Dale J. Finding a pathway: information and uncertainty along the prostate cancer patient journey. Br J Health Psychol. 2009;14(3):437–58.CrossRef
11.
go back to reference Holland JC, Andersen B, Breitbart WS, Compas B, Dudley MM, Fleishman S, Fulcher CD, Greenberg DB, Greiner CB, Handzo GF, et al. Distress management. J Natl Compr Cancer Netw. 2010;8(4):448–85.CrossRef Holland JC, Andersen B, Breitbart WS, Compas B, Dudley MM, Fleishman S, Fulcher CD, Greenberg DB, Greiner CB, Handzo GF, et al. Distress management. J Natl Compr Cancer Netw. 2010;8(4):448–85.CrossRef
12.
go back to reference Sharpley CF, Christie DR, Bitsika V. Do hormone treatments for prostate cancer cause anxiety and depression? Int J Clin Oncol. 2014;19(3):523–30.CrossRef Sharpley CF, Christie DR, Bitsika V. Do hormone treatments for prostate cancer cause anxiety and depression? Int J Clin Oncol. 2014;19(3):523–30.CrossRef
13.
go back to reference Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, Ozakinci G. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013;7(3):300–22.CrossRef Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, Ozakinci G. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013;7(3):300–22.CrossRef
14.
go back to reference Nelson CJ, Weinberger MI, Balk E, Holland J, Breitbart W, Roth AJ. The chronology of distress, anxiety, and depression in older prostate cancer patients. Oncologist. 2009;14(9):891–9.CrossRef Nelson CJ, Weinberger MI, Balk E, Holland J, Breitbart W, Roth AJ. The chronology of distress, anxiety, and depression in older prostate cancer patients. Oncologist. 2009;14(9):891–9.CrossRef
15.
go back to reference Lehuluante A, Fransson P. Are there specific health-related factors that can accentuate the risk of suicide among men with prostate cancer? Support Care Cancer. 2014;22(6):1673–8.CrossRef Lehuluante A, Fransson P. Are there specific health-related factors that can accentuate the risk of suicide among men with prostate cancer? Support Care Cancer. 2014;22(6):1673–8.CrossRef
16.
go back to reference Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Support Care Cancer. 2001;9(3):187–98.PubMed Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Support Care Cancer. 2001;9(3):187–98.PubMed
17.
go back to reference Koo KC, Park SU, Kim KH, Rha KH, Hong SJ, Yang SC, Chung BH. Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. Prostate Int. 2015;3(1):10–5.CrossRef Koo KC, Park SU, Kim KH, Rha KH, Hong SJ, Yang SC, Chung BH. Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. Prostate Int. 2015;3(1):10–5.CrossRef
18.
go back to reference Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer. 2005;104(3):467–78.CrossRef Dale W, Bilir P, Han M, Meltzer D. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer. 2005;104(3):467–78.CrossRef
19.
go back to reference Tavlarides AM, Ames SC, Diehl NN, Joseph RW, Castle EP, Thiel DD, Broderick GA, Parker AS. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psychooncology. 2013;22(6):1328–35.CrossRef Tavlarides AM, Ames SC, Diehl NN, Joseph RW, Castle EP, Thiel DD, Broderick GA, Parker AS. Evaluation of the association of prostate cancer-specific anxiety with sexual function, depression and cancer aggressiveness in men 1 year following surgical treatment for localized prostate cancer. Psychooncology. 2013;22(6):1328–35.CrossRef
20.
go back to reference Parker PA, Kudelka A, Basen-Engquist K, Kavanagh J, de Moor J, Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol. 2006;100(3):495–500.CrossRef Parker PA, Kudelka A, Basen-Engquist K, Kavanagh J, de Moor J, Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol. 2006;100(3):495–500.CrossRef
21.
go back to reference Simard S, Savard J, Ivers H. Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. J Cancer Surviv. 2010;4(4):361–71.CrossRef Simard S, Savard J, Ivers H. Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. J Cancer Surviv. 2010;4(4):361–71.CrossRef
22.
go back to reference Kazer MW, Harden J, Burke M, Sanda MG, Hardy J, Bailey DE. The experiences of unpartnered men with prostate cancer: a qualitative analysis. J Cancer Surviv. 2011;5(2):132–41.CrossRef Kazer MW, Harden J, Burke M, Sanda MG, Hardy J, Bailey DE. The experiences of unpartnered men with prostate cancer: a qualitative analysis. J Cancer Surviv. 2011;5(2):132–41.CrossRef
23.
go back to reference Kamen C, Mustian KM, Heckler C, Janelsins MC, Peppone LJ, Mohile S, McMahon JM, Lord R, Flynn PJ, Weiss M, et al. The association between partner support and psychological distress among prostate cancer survivors in a nationwide study. J Cancer Surviv. 2015;9(3):492–9.CrossRef Kamen C, Mustian KM, Heckler C, Janelsins MC, Peppone LJ, Mohile S, McMahon JM, Lord R, Flynn PJ, Weiss M, et al. The association between partner support and psychological distress among prostate cancer survivors in a nationwide study. J Cancer Surviv. 2015;9(3):492–9.CrossRef
24.
go back to reference Ettridge KA, Bowden JA, Chambers SK, Smith DP, Murphy M, Evans SM, Roder D, Miller CL. “Prostate cancer is far more hidden...”: Perceptions of stigma, social isolation and help-seeking among men with prostate cancer. Eur JCancer Care. 2018;27(2):e12790.CrossRef Ettridge KA, Bowden JA, Chambers SK, Smith DP, Murphy M, Evans SM, Roder D, Miller CL. “Prostate cancer is far more hidden...”: Perceptions of stigma, social isolation and help-seeking among men with prostate cancer. Eur JCancer Care. 2018;27(2):e12790.CrossRef
25.
go back to reference Sharpley CF, Bitsika V, Wootten AC, Christie DR. Differences in major depressive disorder and generalised anxiety disorder symptomatology between prostate cancer patients receiving hormone therapy and those who are not. Psychooncology. 2014;23(12):1350–5.CrossRef Sharpley CF, Bitsika V, Wootten AC, Christie DR. Differences in major depressive disorder and generalised anxiety disorder symptomatology between prostate cancer patients receiving hormone therapy and those who are not. Psychooncology. 2014;23(12):1350–5.CrossRef
26.
go back to reference Johanes C, Monoarfa RA, Ismail RI, Umbas R. Anxiety level of early- and late-stage prostate cancer patients. Prostate Int. 2013;1(4):177–82.CrossRef Johanes C, Monoarfa RA, Ismail RI, Umbas R. Anxiety level of early- and late-stage prostate cancer patients. Prostate Int. 2013;1(4):177–82.CrossRef
27.
go back to reference Orom H, Nelson CJ, Underwood W 3rd, Homish DL, Kapoor DA. Factors associated with emotional distress in newly diagnosed prostate cancer patients. Psychooncology. 2015;24(11):1416–22.CrossRef Orom H, Nelson CJ, Underwood W 3rd, Homish DL, Kapoor DA. Factors associated with emotional distress in newly diagnosed prostate cancer patients. Psychooncology. 2015;24(11):1416–22.CrossRef
28.
go back to reference King AJL, Evans M, Moore THM, Paterson C, Sharp D, Persad R, Huntley AL. Prostate cancer and supportive care: a systematic reviewand qualitative synthesis of men’s experiences and unmet needs. Eur J Cancer Care. 2015;24:618–34.CrossRef King AJL, Evans M, Moore THM, Paterson C, Sharp D, Persad R, Huntley AL. Prostate cancer and supportive care: a systematic reviewand qualitative synthesis of men’s experiences and unmet needs. Eur J Cancer Care. 2015;24:618–34.CrossRef
29.
go back to reference Fransson P. Quality of life for members of Swedish prostate Cancer patient associations. Cancer Nurs. 2008;31(1):23–31.CrossRef Fransson P. Quality of life for members of Swedish prostate Cancer patient associations. Cancer Nurs. 2008;31(1):23–31.CrossRef
30.
go back to reference Carlsson C, Baigi A, Killander D, Larsson US. Motives for becoming and remaining member of patient associations: a study of 1,810 Swedish individuals with cancer associations. Support Care Cancer. 2005;13(12):1035–43.CrossRef Carlsson C, Baigi A, Killander D, Larsson US. Motives for becoming and remaining member of patient associations: a study of 1,810 Swedish individuals with cancer associations. Support Care Cancer. 2005;13(12):1035–43.CrossRef
31.
go back to reference Fossa SD, Bengtsson T, Borre M, Ahlgren G, Rannikko A, Dahl AA. Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries. Scand J Urol. 2016;50(5):330–7.CrossRef Fossa SD, Bengtsson T, Borre M, Ahlgren G, Rannikko A, Dahl AA. Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries. Scand J Urol. 2016;50(5):330–7.CrossRef
32.
go back to reference Fossa SD, Dahl AA. Global quality of life after curative treatment for prostate Cancer: what matters? A study among members of the Norwegian prostate Cancer patient association. Clin Genitourin Cancer. 2015;13(6):518–24.CrossRef Fossa SD, Dahl AA. Global quality of life after curative treatment for prostate Cancer: what matters? A study among members of the Norwegian prostate Cancer patient association. Clin Genitourin Cancer. 2015;13(6):518–24.CrossRef
Metadata
Title
Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden
Authors
Ulrika Rönningås
Per Fransson
Maja Holm
Agneta Wennman-Larsen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2019
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-019-0493-1

Other articles of this Issue 1/2019

BMC Urology 1/2019 Go to the issue